[1]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216-220.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):216-220.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
点击复制

18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第4期
页码:
216-220
栏目:
论著
出版日期:
2013-07-25

文章信息/Info

Title:
Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer
作者:
林美福;  陈文新;  周硕;  郭莘;  陈彩龙;  陈国宝;  戴红峰
350001 福州, 福建医科大学省立临床医学院, 福建省立医院核医学科
Author(s):
LIN Mei-fu;  CHEN Wen-xin;  ZHOU Shuo;  GUO Xin;  CHEN Cai-long;  CHEN Guo-bao;  DAI Hong-feng
Department of Nuclear Medicine, Provincial Clinical College, Fujian Medical University, Fuzhou 350001, China
关键词:
受体; 雌激素; 乳腺肿瘤; 雌二醇; 氟脱氧葡萄糖F18; 正电子发射断层显像术; 体层摄影术; X线计算机
Keywords:
Receptors; estrogen; Breast neoplasms; Estradiol; Fluorodeoxyglucose F18; Positronemission tomography; Tomography; X-ray computed
DOI:
10.3760/cma.j.issn.1673-4114.2013.04.007
摘要:
目的 探讨16α-[18F]氟-17β-雌二醇(18F-FES)PET/CT显像在乳腺癌诊疗中的应用价值。方法 对19例乳腺癌术前患者、7例乳腺癌术后转移患者行18F-FDG、18F-FES PET双显像剂显像,并与雌激素受体(ER)的表达情况进行对照分析。结果 19例乳腺癌术前患者中,乳腺癌原发灶ER阳性者9例,共10个病灶,18F-FES最大标准化摄取值(SUVmax)为3.45±2.34,与病灶的ER表达水平及病灶大小均密切相关;ER阴性者10例,共11个病灶,18F-FES SUVmax为0.74±0.12,两组间差异有统计学意义(t=3.782,P<0.01)。而ER阳性者和阴性者的18F-FDGSUVmax与病灶的ER表达水平无关。18F-FES PET/CT诊断原发灶ER阳性的灵敏度、特异度、准确率分别为100%、90.90%、95.23%。在7例术后转移患者中,原发灶ER阳性者3例,18F-FES共发现64个转移灶,而18F-FDG仅发现47个。结论 18F-FES PET/CT在ER阳性乳腺癌的特异性诊断、个性化治疗方案制定、疗效观察中具有非常重要的临床意义。
Abstract:
Objective To evaluate the role of 16α-[18F]fluoro-17β-oestradiol(18F-FES)PET/CT in the diagnosis and management of breast cancer.Methods Nineteen pre-operation cases with breast cancer and 7 post-operation cases with metastatic breast cancer underwent 18F-FES PET/CT and 18F-FDG PET/CT,and comparative analysis with the expression of estrogen receptor (ER)was performed.Results Of the primary lesions,the ER was positive in 9 patients (10 lesions),negative in 10 patients (11 lesions).The maximum standardized uptake value (SUVmax) for FES uptake was positively related to the lesion size and ER expression.The mean SUVmax for FES uptake was 3.45±2.34 in the 10 ER positive tumors,and 0.74±0.12 in the 11 ER negative tumors,which showed significant differences between the two groups (t=3.782,P<0.01).The sensitivity,specificity and accuracy of FES PET for diagnosis ER positive patients were 100%,90.90% and 95.23% respectively.Sixty-four 18F-FES positive metastases were found in the three ER positive metastatic patients,whereas only 47 18F-FDG positive metastases were found.Conclusion 18F-FES PET/CT will be useful for diagnosis,individualized medicine and detecting therapeutic changes in patients with ER positive breast cancer.

参考文献/References:

[1] Hospers GA, Helmond FA, de Vries EG, et al. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des, 2008, 14(28):3020-3032.
[2] Kumar P, Mercer J, Doerkson C, et al. Clinical production, stability studies and PET imaging with 16-alpha-[18F]-fluoroestradiol ([18F]-FES) in ER positive breast cancer patients. J Pharm Pharm Sci, 2007, 10(2):256s-265s.
[3] Mortimer JE, Dehdashti F, Siegel BA, et al. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16α-[18F]-17β-estradiol in breast cancer:correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res, 1996, 2(6):933-939.
[4] Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 2005, 35(2):84-99.
[5] Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol, 2006, 24(18):2793-2799.
[6] Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res, 2011,17(14):4799-4805.
[7] van Kruchten M, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med, 2012, 53(2):182-190.
[8] Tsujikawa T, Yoshida Y, Kudo T, et al. Functional images reflect aggressiveness of endometrial carcinoma:estrogen receptor expression combined with 18F-FDG PET. J Nucl Med, 2009, 50(10):1598-1604.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
　Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
　Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[5]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
　Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[6]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
　ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[7]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
　YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[8]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
　BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[9]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
　CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[10]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
　HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[11]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
　Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[12]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
　LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(4):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[13]孟召伟,董峰,谭建.乳腺癌的雌激素受体显像[J].国际放射医学核医学杂志,2007,31(3):157.
　MENG Zhao-wei,DONG Feng,TAN Jian.Estrogen receptor imaging in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):157.

备注/Memo

备注/Memo:
收稿日期:2012-09-29。
通讯作者:陈文新,Email:wenxinchzt@aliyun.com
更新日期/Last Update: 1900-01-01